V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330008808 | 330005604 | 1.6 | 66.6 | Palliative (P) | 2015-09-07 | 2015-09-07 | Dox + HD Mtx (post PAM) | 2 | N | 330021673 | DOXORUBICIN + HD MTX |
| 330008809 | 330010918 | null | 80.6 | Curative (C) | null | 2013-12-09 | Mitotane 5.5 - 10g | null | N | 330021674 | VDC |
| 330008810 | 330009060 | 1.72 | 0 | null | 2016-08-14 | 2016-08-14 | CHOP R - 21 days | N | N | 330021690 | CYCLOPHOSPHAMIDE + VINCRISTINE + LIPOSOMAL DOXORUBICIN |
| 330008811 | 330009060 | 1.62 | 45.25 | Curative (C) | 2016-06-14 | 2016-06-14 | Cytarabine+Methotrexate Intrathecal | 02 | null | 330021690 | GEMCITABINE |
| 330008812 | 330005607 | 1.62 | null | Palliative (P) | null | 2015-08-28 | Clofarabine + Cytarabine | null | N | 330021695 | HYDROXYCARBAMIDE |
| 330008813 | 330009061 | null | 71.1 | Disease modification (D) | 2017-12-16 | 2017-12-22 | Cisplatin + Paclitaxel | N | N | 330021695 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330008814 | 330009061 | 1.76 | 66 | Palliative (P) | 2017-01-01 | 2017-05-31 | CISPLATIN + GEMCITABINE | 02 | Y | 330021695 | AML17 TRIAL |
| 330008815 | 330005609 | null | 72.2 | Palliative (P) | 2017-10-26 | 2017-12-20 | CISPLATIN + ETOPOSIDE + PACLITAXEL | N | N | 330021732 | RMS 2005 TRIAL |
| 330008816 | 330005610 | 1.59 | 14.9 | null | 2014-05-18 | 2014-05-22 | EMA | 02 | N | 330021734 | PAC-PLAT |
| 330008817 | 330009063 | 1.55 | null | Palliative (P) | 2017-11-30 | 2017-12-06 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | 330021739 | IVA |
| 330008818 | 330005618 | 1.79 | 61.6 | Palliative (P) | 2016-08-20 | 2016-08-20 | GEMCITABINE + OXALIPLATIN + PACLITAXEL | 02 | N | 330021746 | IPO |
| 330008819 | 330005618 | 1.55 | 62.7 | Adjuvant (A) | 2018-02-09 | 2018-03-13 | Capecitabine | 02 | N | 330021746 | IPO |
| 330008820 | 330005618 | 1.62 | 66.6 | Adjuvant (A) | 2016-06-04 | 2016-06-05 | Busulfan po + Fludarabine RIC Allo | 2 | null | 330021746 | TREOSULFAN |
| 330008821 | 330005619 | 1.81 | 35.75 | Adjuvant (A) | 2017-01-20 | 2017-01-24 | Hydroxycarbamide | N | N | 330021811 | CYTARABINE |
| 330008822 | 330005619 | 1.58 | 64.1 | Curative (C) | null | 2017-12-24 | GEMCITABINE | null | N | 330021811 | MA |
| 330008823 | 330005619 | 1.78 | 82 | Adjuvant (A) | 2014-07-13 | 2014-07-19 | ALL UKALL60+ TRIAL | Y | N | 330021811 | FBC |
| 330008824 | 330010923 | 1.64 | 53.1 | Neo-adjuvant (N) | 2016-07-17 | 2017-04-07 | Pazopanib | N | N | 330021874 | UKALL2014 |
| 330008825 | 330011945 | 1.41 | 0 | Neo-adjuvant (N) | 2018-07-10 | 2018-07-10 | CVP R | 02 | N | 330021874 | DOXORUBICIN + HD MTX |
| 330008826 | 330005622 | 1.8 | 46.05 | null | 2017-11-11 | 2017-11-14 | Cytarabine low (10to20mg/m2) IV/SC | 02 | N | 330021899 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330008827 | 330010924 | 1.84 | null | Neo-adjuvant (N) | 2013-09-25 | 2013-10-17 | Ifosfamide | null | null | 330021924 | ICE |
| 330008828 | 330011946 | 1.7 | 87.8 | Palliative (P) | 2016-09-03 | 2016-09-21 | VIDE | N | N | 330021927 | CVP |
| 330008829 | 330011946 | 1.26 | null | Curative (C) | 2014-09-08 | 2014-09-30 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | N | 330021927 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330008830 | 330005624 | 1.76 | null | Neo-adjuvant (N) | 2017-08-13 | 2017-08-20 | Ifosfamide | N | N | 330021951 | IPILIMUMAB |
| 330008831 | 330005625 | 1.55 | 68.2 | Curative (C) | null | 2013-08-01 | UKALL14- Ph 2 Induction | null | N | 330021970 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 330008832 | 330005626 | 1.58 | 85 | Curative (C) | 2015-02-07 | 2015-02-15 | CARBOPLATIN + CETUXIMAB + FU | 2 | N | 330021973 | TRIPLE INTRATHECAL |
| 330008833 | 330010925 | 1.81 | 55.6 | Adjuvant (A) | 2015-06-25 | 2015-07-07 | CAPECITABINE + CARBOPLATIN + Cetuximab | 02 | N | 330021973 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330008834 | 330005627 | 1.64 | null | Neo-adjuvant (N) | 2015-06-20 | 2015-07-12 | Packer Maintenance Regimen | N | N | 330022010 | IBRUTINIB |
| 330008835 | 330005629 | 1.8 | 44.3 | Palliative (P) | 2018-06-11 | 2018-06-16 | FCR IV - Cycle 2 onwards | 02 | N | 330022010 | DOXORUBICIN + OLARATUMAB |
| 330008836 | 330012870 | 1.78 | 62.5 | Neo-adjuvant (N) | 2016-09-04 | 2016-09-07 | CISPLATIN + DOXORUBICIN + METHOTREXATE | 02 | N | 330022051 | ESHAP |
| 330008837 | 330005630 | 1.61 | 63 | Curative (C) | 2017-08-03 | 2017-08-06 | STS Rhabdomyosarcoma RMS 2005 VA | N | null | 330022092 | DOXORUBICIN + HD MTX |
| 330008838 | 330005631 | 1.64 | 12.7 | Palliative (P) | 2013-09-15 | 2013-10-25 | EMA | N | N | 330022105 | DACTINOMYCIN |
| 330008839 | 330005633 | 1.62 | 63 | Palliative (P) | 2015-08-11 | 2015-08-23 | EP | 2 | N | 330022131 | NILOTINIB |
| 330008840 | 330005635 | 1.56 | 16.4 | Palliative (P) | 2013-09-24 | 2013-09-24 | ICE | 2 | N | 330022135 | CARBOPLATIN + PEMETREXED |
| 330008841 | 330005635 | 1.57 | 51.5 | Palliative (P) | 2018-07-14 | 2018-07-20 | ALL UKALL2011 Consolidation A | N | N | 330022135 | IVA |
| 330008842 | 330005639 | 1.79 | 70.4 | Curative (C) | 2015-09-20 | 2015-09-27 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 330022163 | CAPECITABINE + IRINOTECAN |
| 330008843 | 330009076 | 0 | 77.95 | Neo-adjuvant (N) | 2013-06-13 | 2013-06-14 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 330022167 | CYTARABINE INTRATHECAL |
| 330008844 | 330010929 | 1.67 | 92.4 | Neo-adjuvant (N) | 2014-01-12 | 2014-01-19 | CYTARABINE | N | N | 330022216 | ALEMTUZUMAB |
| 330008845 | 330011949 | null | 91.6 | Neo-adjuvant (N) | 2014-10-02 | 2014-10-05 | IMMUNOGLOBULIN | null | null | 330022219 | LIPOSOMAL DAUNORUBICIN |
| 330008846 | 330009077 | 1.72 | 30.1 | Curative (C) | null | 2014-10-05 | CVP | null | N | 330022232 | DOXORUBICIN + HD MTX |
| 330008847 | 330010930 | 1.8 | 23.3 | Palliative (P) | 2017-07-13 | 2017-07-19 | BORTEZOMIB + RITUXIMAB | 02 | N | 330022242 | LIPOSOMAL DAUNORUBICIN |
| 330008848 | 330005644 | 0 | 65 | Palliative (P) | 2017-02-07 | 2017-02-14 | Dox + HD Mtx (post PAM) | 02 | N | 330022242 | MAP + MIFAMURTIDE |
| 330008849 | 330005646 | 1.52 | null | Curative (C) | 2018-12-15 | 2018-12-26 | CVP R | N | N | 330022274 | FLAG |
| 330008850 | 330005648 | 1.61 | 44 | null | 2013-09-18 | 2013-09-18 | CYCLO + DOXORUBICIN + VINCRISTINE | 2 | N | 330022274 | EMA/CO |
| 330008851 | 330005651 | null | null | Palliative (P) | 2014-08-03 | 2014-08-05 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | 330022321 | IFOSFAMIDE |
| 330008852 | 330005651 | 1.75 | null | Curative (C) | 2018-01-18 | 2018-04-29 | Carboplatin + Liposomal Doxorubicin | N | N | 330022321 | GCLAC |
| 330008853 | 330005651 | 1.64 | 110 | Adjuvant (A) | 2015-09-08 | 2015-09-08 | Hydroxycarbamide | 02 | N | 330022321 | UKALL2014 |
| 330008854 | 330005652 | null | 70 | Disease modification (D) | null | 2017-01-25 | Dox + HD Mtx (post PAM) | null | N | 330022329 | CYCLOPHOSPHAMIDE |
| 330008855 | 330005653 | 1.65 | 61.6 | Palliative (P) | 2014-12-13 | 2014-12-13 | Ipilimumab | N | null | 330022349 | GEMCITABINE |
| 330008856 | 330009085 | 0 | 48.6 | Palliative (P) | 2014-03-19 | 2014-03-21 | Carboplatin + Cetux + FU (>Cycle 2) | 2 | N | 330022355 | CYCLO + ETOPOSIDE + VINCRISTINE |
| 330008857 | 330011951 | 1.7 | 74 | Palliative (P) | 2016-02-20 | 2016-07-02 | Dox + HD Mtx (post PAM) | 02 | N | 330022355 | BLEOMYCIN + CISPLATIN + ETOPOSIDE |